Literature DB >> 11156554

Cardiostimulant effects of urotensin-II in human heart in vitro.

F D Russell1, P Molenaar, D M O'Brien.   

Abstract

The effects of the recently identified human peptide urotensin-II (hU-II) were investigated on human cardiac muscle contractility and coronary artery tone. In right atrial trabeculae from non-failing hearts, hU-II caused a concentration-dependent increase in contractile force (pEC(50)=9.5+/-0.1; E(max)=31.3+/-4.8% compared to 9.25 mM Ca(2+); n=9) with no change in contraction duration. In right ventricular trabeculae from explanted hearts, 20 nM hU-II caused a small increase in contractile force (7.8+/-1.4% compared to 9.25 mM Ca(2+); n=3/6 tissues from 2 out of 4 patients). The peptide caused arrhythmic contractions in 3/26 right atrial trabeculae from 3/9 patients in an experimental model of arrhythmia and therefore has less potential to cause arrhythmias than ET-1. hU-II (20 nM) increased tone (17.9% of the response to 90 mM KCI) in 7/7 tissues from 1 patient, with no response detected in 8/8 tissues from 2 patients. hU-II is a potent cardiac stimulant with low efficacy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11156554      PMCID: PMC1572555          DOI: 10.1038/sj.bjp.0703811

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat.

Authors:  M R MacLean; D Alexander; A Stirrat; M Gallagher; S A Douglas; E H Ohlstein; I Morecroft; K Polland
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14).

Authors:  M Mori; T Sugo; M Abe; Y Shimomura; M Kurihara; C Kitada; K Kikuchi; Y Shintani; T Kurokawa; H Onda; O Nishimura; M Fujino
Journal:  Biochem Biophys Res Commun       Date:  1999-11       Impact factor: 3.575

3.  Functional receptors for fish neuropeptide urotensin II in major rat arteries.

Authors:  H Itoh; D McMaster; K Lederis
Journal:  Eur J Pharmacol       Date:  1988-04-27       Impact factor: 4.432

4.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.

Authors:  R S Ames; H M Sarau; J K Chambers; R N Willette; N V Aiyar; A M Romanic; C S Louden; J J Foley; C F Sauermelch; R W Coatney; Z Ao; J Disa; S D Holmes; J M Stadel; J D Martin; W S Liu; G I Glover; S Wilson; D E McNulty; C E Ellis; N A Elshourbagy; U Shabon; J J Trill; D W Hay; E H Ohlstein; D J Bergsma; S A Douglas
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

5.  A 5-hydroxytryptamine receptor in human atrium.

Authors:  A J Kaumann; L Sanders; A M Brown; K J Murray; M J Brown
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

6.  Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

7.  Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries.

Authors:  Y Katano; A Ishihata; T Aita; T Ogaki; T Horie
Journal:  Eur J Pharmacol       Date:  2000-08-18       Impact factor: 4.432

8.  Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670.

Authors:  K M Burrell; P Molenaar; P J Dawson; A J Kaumann
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

9.  Studies on molecular weights of two peptide hormones from the urophysis of white sucker (Catostomus commersoni).

Authors:  G Moore; A Letter; M Tesanovic; K Lederis
Journal:  Can J Biochem       Date:  1975-02

10.  Chemical synthesis of urotensin II, a somatostatin like peptide in the caudal neurosecretory system of fishes.

Authors:  B R Clark; J Dattilo; D Pearson
Journal:  Int J Pept Protein Res       Date:  1982-05
View more
  29 in total

Review 1.  Cardiovascular actions of human urotensin II--considerations for hypertension.

Authors:  Fraser D Russell; Peter Molenaar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

2.  Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling.

Authors:  Ana Patrícia Fontes-Sousa; Carmen Brás-Silva; Ana Luísa Pires; Daniela Monteiro-Sousa; Adelino F Leite-Moreira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-14       Impact factor: 3.000

Review 3.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 4.  Is urotensin-II the new endothelin?

Authors:  Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

5.  Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II.

Authors:  Joan Li; Jianchun Wang; Fraser D Russell; Peter Molenaar
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

6.  Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.

Authors:  David J Behm; Stephen M Harrison; Zhaohui Ao; Kristeen Maniscalco; Susan J Pickering; Evelyn V Grau; Tina N Woods; Robert W Coatney; Christopher P A Doe; Robert N Willette; Douglas G Johns; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

7.  The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.

Authors:  Christopher L Herold; David J Behm; Peter T Buckley; James J Foley; William E Wixted; Henry M Sarau; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

8.  PPAR-gamma expression in animals subjected to volume overload and chronic Urotensin II administration.

Authors:  Gregory S Harris; Robert M Lust; Jonathan H DeAntonio; Laxmansa C Katwa
Journal:  Peptides       Date:  2008-03-12       Impact factor: 3.750

9.  Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain.

Authors:  Antony A Boucard; Simon S Sauvé; Gaétan Guillemette; Emanuel Escher; Richard Leduc
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

10.  Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.

Authors:  David J Behm; Christopher L Herold; Eliot H Ohlstein; Steven D Knight; Dashyant Dhanak; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.